Next Article in Journal
Mucoepidermoid Carcinoma of the Uterine Cervix—Single-Center Study Over a 10-Year Period
Next Article in Special Issue
Prognostic Markers of Myelodysplastic Syndromes
Previous Article in Journal
Integrative Medicine in Interventional Oncology: A Virtuous Alliance
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 56
Issue 1
10.3390/medicina56010036
Review Report
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies

Medicina 2020, 56(1), 36; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina56010036
by Ida Marie Rundgren 1,2, Elisabeth Ersvær 1, Aymen Bushra Ahmed 3, Anita Ryningen 1 and Øystein Bruserud 2,3,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Medicina 2020, 56(1), 36; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina56010036
Submission received: 22 November 2019 / Revised: 30 December 2019 / Accepted: 15 January 2020 / Published: 18 January 2020
(This article belongs to the Special Issue Acute Myeloid Leukemia and Myelodysplastic Syndromes: Biological and Clinical Implications)

Round 1

Reviewer 1 Report

In this paper authors show an expected normalization of monocytes after stem cell transplantation.

Line 59: Authors should define “early” reconstitution

Introduction section: please explain your aim and hypothesis, why this research needed? Clinical implications?

Suggest to move lines 124-132 to methods section, start results section by describing the demographics of your patients.

Results section: authors describe 13 patients, but table has 16 patients, I suggest to include only patients that authors studied

Discussion: authors should not only state their finding, but also elaborate its impotence, clinical significance?

Line 315: please avoid using high risk leukemia, a nebulous term, state accepted terminology AML or high-risk MDS

Line 316:  “a greater variation in the distribution of monocyte” : greater from what?

the patient cohort is small and heterogeneous; AML, MDS, APL, PLL, also some got autologous most got the allogeneic transplant. it is difficult to draw any reliable conclusion. I suggest authors to focus one disease group and transplant modality.

 

Author Response

Please see the  attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Line 40: Please consider mentioning about the novel therapies in AML as there are subtypes in which intensive chemotherapy and transplant are not the standard.

Line 45: Please mention that the age of transplant depends on the institution and the fraility of the patient.

Line 55: Please be more specific about CD14 role (more than surface receptor).

Line 120: Please be more specific about your statistical analyses.

Table 1: Please include cytogenetic and/or mutations if available.

Table 2: Please change Table 2 into a swimmers plot.

Figure 2: Please remove Figure 2 or offer a more clear representation.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

authors responded my comments

Back to TopTop